Pricing Log in Create free account

Kura Oncology, Inc. (KURA) vs Nuvectis Pharma, Inc. (NVCT)

Kura Oncology, Inc. and Nuvectis Pharma, Inc. are both Biotechnology companies. Kura Oncology, Inc. and Nuvectis Pharma, Inc. are of similar size ($604.9M and $579.8M). Nuvectis Pharma, Inc. has the higher net margin (0.00% vs −384.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Nuvectis Pharma, Inc. leads on 11 and Kura Oncology, Inc. on 1.

Valuation

Metric KURA NVCT Biotechnology median
P/E n/m n/m 10.60
P/S 8.31 n/m 9.40
P/B 13.25 4.84 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 1.71 n/m 9.02
Earnings yield (46.68%) (9.08%) (32.88%)
Free cash flow yield (18.30%) (6.57%) (23.13%)

Profitability

Metric KURA NVCT Biotechnology median
Gross margin 99.35% — 68.51%
Operating margin (411.90%) 0.00% 0.00%
Net margin (384.30%) 0.00% 0.00%
Free cash flow margin (152.06%) 0.00% 0.00%
Return on equity (167.71%) (66.98%) (51.96%)
Return on assets (46.73%) (57.20%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric KURA NVCT Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (57.43%) (18.92%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KURA NVCT Biotechnology median
Debt to equity 0.20 0.00 0.00
Current ratio 4.73 9.92 4.97
Net debt to EBITDA 2.11 1.15 1.01

Dividend

Metric KURA NVCT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KURA NVCT Biotechnology median
Market cap 604.93m 579.76m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack